Juno: CPE, Mirae lead $100m Series B for China's JW Therapeutics

JW Therapeutics, a China cancer treatment specialist established by Bristol Myers Squibb-owned Juno Therapeutics and China's WuXi AppTec, has received $100 million in Series B funding.